41 – 50 of 76
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Effect of adding gefitinib to neoadjuvant chemotherapy in estrogen receptor negative early breast cancer in a randomized phase II trial
(
- Contribution to journal › Article
-
Mark
High-resolution genomic profiling of male breast cancer reveals differences hidden behind the similarities with female breast cancer
(
- Contribution to journal › Article
-
Mark
Value of post-operative reassessment of estrogen receptor alpha expression following neoadjuvant chemotherapy with or without gefitinib for estrogen receptor negative breast cancer
(
- Contribution to journal › Article
-
Mark
Regarding the article "The p160 ER co-regulators predict outcome in ER negative breast cancer" by Spears, Oesterreich, Migliaccio et al. published in Breast Cancer Res Treat, March 2011.
(
- Contribution to journal › Article
- 2010
-
Mark
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study
(
- Contribution to journal › Article
-
Mark
Breast cancer risk in women who fulfill high-risk criteria: at what age should surveillance start?
(
- Contribution to journal › Article
-
Mark
Genetic variants on chromosome 5p12 are associated with risk of breast cancer in African American women: the Black Women's Health Study
(
- Contribution to journal › Article
-
Mark
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
(
- Contribution to journal › Article
-
Mark
Changing clinical presentation of angiosarcomas after breast cancer: from late tumors in edematous arms to earlier tumors on the thoracic wall.
(
- Contribution to journal › Article
-
Mark
Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.
(
- Contribution to journal › Article